Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker

Journal of Clinical Pathology

Volumn 60, Issue 7, 2007, Pages 804-807

  Sulzbacher, Irene ^a   Birner, Peter ^a   Toma, Cyril ^a   Wick, Nikolaus ^a   Mazal, Peter R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE FREE SURVIVAL; DNA SEQUENCE; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447323857     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.032839     Document Type: Article

References (23)

1. Dorfman HD, Czerniak B. Osteosarcoma. In: Dorfman HD, Czerniak B, eds. Bone tumors, 1st edn. St Louis, MO: Mosby, 1998:128-252.
2. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J Clin Oncol 2005;23:559-68.
3. Mankin HJ, Hornicek FJ, Rosenberg AE, et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004;429:286-91.
4. Kasre SC, Liu T, Billups CA, et al. Tumor size as a predictor of outcome in pediatric non- metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 2004;43:723-8.
5. Fellenberg J, Krauthoff A, Pollandt K, et al. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 2004;84:113-21.
6. Tsai JY, Aviv H, Benevenia J, et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 2004;22:16-24.
7. Lee WI, Bacchni P, Bertoni F, et al. Quantitative assessment of HER-2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma. Oncol Rep 2004;12:125-8.
8. Pakos EE, Kyzas PA, loannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a metaanalysis. Clin Cancer Res 2004;10:6204-14.
9. Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: a predictive, multicenrer study. J Clin Oncol 2005;23:1483-90.
10. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005;65:1748-54.
11. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;2346:683-93.
12. Seidal T. Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999;34:416-24.
13. Chang JK. Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal disease? Adv Anat Pathol 1999;6:19-40.
14. de Mestier P, des Guetz G. Treatment of gastrointestinal stroma rumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J Surg 2005;29:357-61.
15. Baselga J, Arribas J. Treating cancer's kinase "addiction". Nat Med 2004;10:786-87.
16. Won Kim T, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal rumors. Clin Cancer Res 2004;10:3076-81.
17. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutation analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
18. Homick JL, Fletcher CD. Immunohistochemical staining for Kit (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-93.
19. Entz-Wede N, Marcellin L, Gaub MP, et al. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas. J Clin Oncol 2005;23:2248-55.
20. Entz-Werie N, Vezuli A, Marec-Berard P, et al. Microsatellite rearrangements of 4q 12 locus and status of the candidate gene c-kit in pediatric osteosarcomas [abstract]. Proc Am Assoc Cancer Res 2005;46.
21. Sulzbacher I, Tröxler M, Mosberger I, et al. Platelet-derived growth factor-AA and -α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000;13:632-37.
22. Sulzbacher I, Bimer P, Trieb K, et al. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003;16:66-71.
23. Yoshitani K, Honoki K, Morishita T, et al. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571. In Vivo 2003;17:255-8.